Twenty-three patients with de novo acute myeloid leukemia (AML) and t (8; 21)(q22; q22),
including 2 children aged 7 and 14 and 21 adults aged 16 to 68 (median 29), were treated …

Nine acute myelogenous leukemia (AML) patients with a translocation 8; 21, who were
treated at Keio University Hospital between 1983 and August 1990, were reviewed. All of …

While the t (8; 21) translocation is one of the most recurrent chromosomal abnormalities in
acute myeloid leukemia, prognostic studies have been hampered by the relatively few …

The t (9; 11)(p21; q23) has been associated with characteristic clinical features and a
superior treatment outcome in previously untreated pediatric acute myeloblastic leukemia …

Following reports of childhood acute myeloid leukemia (AML) showing that patients with t (9;
11)(p22; q23) have a better prognosis than those with translocations between 11q23 and …

Purpose: This was a retrospective analysis of outcome based on cytogenetics for a
Children's Cancer Group phase 3 trial of acute myelogenous leukemia (AML)(CCG-2891) …

A retrospective study of 148 previously untreated patients with acute nonlymphocytic
leukemia (ANLL) presenting at (8; 21) was undertaken by the Groupe Français de …

Cytogenetic analysis was successfully performed at diagnosis in 283 patients with de novo
acute myeloid leukaemia (AML), including eight children aged 6–15 and 275 adults. Mean …

The translocation t (8; 21)(q22; q22) occurs in 6 to 12 percent of patients with AML, and
usually predicts a good response to chemotherapy with a high remission rate and a …

The translocation t (8; 21) is one of the most common structural aberrations in acute myeloid
leukemia (AML). Excellent response rates and a better relapse-free survival have been …